SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Centocor ( CNTO )
CNTO 0.000010000.0%Jan 29 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Thean who wrote (80)4/16/1997 8:12:00 AM
From: phil   of 965
 
I don't see prelim Aggrestat results as a major threat to Reopro; Reopro has a tremendous head start in building market share and hopefully an expanded use will be approved by the FDA prior to approval of Aggrestat.
Does anyone have further info on Cent-TNF in Crohn's? Does it help only fistulas, or other symptoms/complications as well?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News